Table 2.
WIP1 overexpression is associated with gain of chromosome 17q or i17q in primary medulloblastoma specimens
| Tumors grouped by CNA | n | WIP1 RNA | P value |
|---|---|---|---|
| +17q MB | 3 | 28.3 | 0.02* |
| i17q MB | 6 | 25.4 | <0.0001* |
| +17q or i17q MB | 9 | 26.3 | <0.00001* |
| Non-17q gain MB | 2 | 6.5 | – |
| WIP1 gain/amplification | 7 | 27.7 | 0.05** |
| Normal WIP1 copy number | 4 | 14.1 | – |
| Tumors analyzed by FISH (subtotal) | 11 | ||
| +17q MB | 5 | 20.2 | 0.0533* |
| i17q MB | 11 | 20.3 | <0.0001* |
| +17q or i17q MB | 16 | 20.3 | <0.00001* |
| Non-17q gain MB | 17 | 5.9 | – |
| All tumors analyzed by CGH (total) | 33 | 13.0 | – |
WIP1 amplification by FISH was associated with increased WIP1 RNA expression by qRT-RTPCR (P = 0.05). Relative WIP1 RNA level was significantly associated with gain 17q, including i17q (P = 0.000001)
*P value: Student t-test of tumors with specified CNA versus tumors without that CNA
**P value: Student t-test of WIP1-ampllified versus non-amplified tumors
Abbreviations: MB, medulloblastoma; +17, gain of chromosome 17; −17, loss of chromosome 17; CNA, copy number aberration